0001209191-22-002979.txt : 20220111 0001209191-22-002979.hdr.sgml : 20220111 20220111194644 ACCESSION NUMBER: 0001209191-22-002979 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220109 FILED AS OF DATE: 20220111 DATE AS OF CHANGE: 20220111 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nau Jeffrey CENTRAL INDEX KEY: 0001791159 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39112 FILM NUMBER: 22525181 MAIL ADDRESS: STREET 1: 202 CARNEGIE CENTER STREET 2: SUITE 109 CITY: PRINCETON STATE: NJ ZIP: 08540 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Oyster Point Pharma, Inc. CENTRAL INDEX KEY: 0001720725 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 811030955 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 202 CARNEGIE CENTER STREET 2: SUITE 109 CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: (609) 382-9032 MAIL ADDRESS: STREET 1: 202 CARNEGIE CENTER STREET 2: SUITE 109 CITY: PRINCETON STATE: NJ ZIP: 08540 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-01-09 0 0001720725 Oyster Point Pharma, Inc. OYST 0001791159 Nau Jeffrey C/O OYSTER POINT PHARMA, INC. 202 CARNEGIE CENTER, SUITE 109 PRINCETON NJ 08540 1 1 0 0 President and CEO Common Stock 2022-01-09 4 A 0 46700 0.00 A 157598 D Common Stock 1000 I See Footnote Employee Stock Option (Right to Buy) 16.00 2022-01-09 4 A 0 210000 0.00 A 2032-01-08 Common Stock 210000 210000 D Represents a grant of restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. 25% of the RSUs vest on January 7, 2023 and the remainder vest annually thereafter, in equal amounts, on the same day of the month as the grant date over the following 3 years, subject to the Reporting Person's continuous service to the Issuer through each such date. These shares are held by the Reporting Person's spouse. Options granted on January 9, 2022 under the Oyster Point Pharma, Inc. 2019 Equity Incentive Plan. 25% of the options shall vest and become exercisable on January 7, 2023 and one thirty-sixth (1/36) of the remaining options shall vest monthly thereafter on the same day of the month (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person's continuous service to the Issuer through each such date. /s/ Brandon Fenn, Attorney-in-Fact 2022-01-11